Latest News

Cambridge, MA, USA.  March 7, 2023.  Shorla Oncology (‘Shorla’), a US-Ireland pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the company’s oncology drug, Nelarabine Injection, for the treatment of T-cell Acute […]

Galway, Ireland. 16 February 2023.  Perfuze, a medical device company developing next-generation catheter-based technology to treat acute ischemic stroke, has secured its first product clearance from the U.S. Food and Drug Administration (FDA) for the company’s […]

Hamilton, ON, Canada and Boston, MA, USA. 13 February 2023.  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) (“Fusion”), a clinical-stage oncology company focused on developing next-generation targeted alpha therapies (“TATs”) as precision medicines, today announced the acquisition from […]

31 January 2023.  Galway, Ireland and Oceanside, California, USA.  Palliare, a leading developer of advanced insufflation technologies, has received an expanded 510(k) indication from the U.S. Food and Drug Administration for its EVA15 Insufflator to provide […]

25 January 2023. Dublin, Ireland.  Deciphex, a leading provider of pathology software and services, announced today a further €3.9m in funding bringing its full Series B round tally to €15m. The additional investment, led by Seroba […]

14 December, 2022. Cambridge, England.    STORM Therapeutics Ltd. (STORM), the clinical biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced the successful completion […]

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top